Southampton researchers lead trials of possible Covid therapy
SOUTHAMPTON researchers are helping to deliver trials of a new therapy which could be used to treat Covid-19.
Source: dailyecho.co.uk
Page 43 - Hal Barron News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Hal Barron. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Hal Barron Today - Breaking & Trending Today
Vir Biotechnology and GSK Announce NHS-Supported AGILE Study to Evaluate VIR-7832 in the Early Treatment of COVID-19
Vir Biotechnology and GSK Announce NHS-Supported AGILE Study to Evaluate VIR-7832 in the Early Treatment of COVID-19 Second monoclonal antibody from Vir-GSK collaboration to be investigated as a potential COVID-19 treatment Preclinical data suggest VIR-7832 has two distinguishing properties: enhanced ability to clear infected cells and potential to enhance virus-specific T cell function, which could help treat and/or prevent COVID-19 infection Trial targeted to begin in 1Q:2021 at multiple sites across the UK SAN FRANCISCO and LONDON, Jan. 12, 2021 (GLOBE NEWSWIRE) — Vir Biotechnology, Inc....
Source: forextv.com
Vir, GSK In Deal With NHS-Supported AGILE To Evaluate VIR-7832 In Early Treatment Of COVID-19
Vir, GSK In Deal With NHS-Supported AGILE To Evaluate VIR-7832 In Early Treatment Of COVID-19 The trial is due to begin in the first quarter of 2021. VIR-7832 is a neutralizing COVID-19 antibody that preclinical data suggests has two distinguishing properties. These are an enhanced ability to clear infected cells and the potential to enhance virus-specific T-cell function, which could help treat and/or prevent COVID-19 infection. The AGILE trial platform will be the first to test VIR-7832 in humans. According to the companies, the AGILE trial platform uses adaptable protocols and statistical ...
Source: finanznachrichten.de
Glaxo Aims to Double Blockbusters in Bid to Revive Portfolio
Glaxo Aims to Double Blockbusters in Bid to Revive Portfolio Bloomberg 1/12/2021 Suzi Ring © Bloomberg The GSK company logo is displayed on a sign outside the GlaxoSmithkline Plc Research and Development center in Stevenage, U.K., on Tuesday, Nov. 26, 2019. Glaxo is exploring the trillions of microbes that inhabit the gut in pursuit of novel ways to prevent some of the world’s most common ailments. (Bloomberg) -- GlaxoSmithKline Plc set an ambitious goal of more than doubling the number of blockbusters in its portfolio by 2026 as the British pharma giant moves to revive...
Source: msn.com
UK antibody trial to test early intervention in patients with mild to moderate Covid-19
The trial is expected to begin in the first quarter of 2021 across multiple UK sites.
Source: cityam.com